Summary of the relevant leukemia-associated characteristics used to MRD in follow-up BM samples of the 108 ALL patients
| ALL . | Aberration* . | Frequency† . | % . |
|---|---|---|---|
| B lineage | CD10 overexpression | 70/100 | 70 |
| (n = 100) | CD45RA underexpression | 32/100 | 32 |
| CD11a underexpression | 22/70 | 31 | |
| CD44 underexpression | 6/68 | 9 | |
| CD19 overexpression | 2/100 | 2 | |
| CD34 overexpression | 9/100 | 9 | |
| CD33 and CD19 cross-lineage coexpression | 5/63 | 8 | |
| IgM‡and CD34 desynchronous coexpression | 9/61 | 15 | |
| CD10 and CD20 desynchronous underexpression1-153 | 5/100 | 5 | |
| T lineage | CD3 (surface) ectopic underexpression | 8/8 | 100 |
| (n = 8) | TdT and CD3 (cytoplasmic) ectopic coexpression | 6/8 | 75 |
| CD7 overexpression | 1/8 | 13 |
| ALL . | Aberration* . | Frequency† . | % . |
|---|---|---|---|
| B lineage | CD10 overexpression | 70/100 | 70 |
| (n = 100) | CD45RA underexpression | 32/100 | 32 |
| CD11a underexpression | 22/70 | 31 | |
| CD44 underexpression | 6/68 | 9 | |
| CD19 overexpression | 2/100 | 2 | |
| CD34 overexpression | 9/100 | 9 | |
| CD33 and CD19 cross-lineage coexpression | 5/63 | 8 | |
| IgM‡and CD34 desynchronous coexpression | 9/61 | 15 | |
| CD10 and CD20 desynchronous underexpression1-153 | 5/100 | 5 | |
| T lineage | CD3 (surface) ectopic underexpression | 8/8 | 100 |
| (n = 8) | TdT and CD3 (cytoplasmic) ectopic coexpression | 6/8 | 75 |
| CD7 overexpression | 1/8 | 13 |
Leukemia-associated phenotypic characteristics.4,5 12-17
Frequency among individual ALL lineages (samples with aberration versus tested specimens; percentage of tested cohort); note that not all leukemic cases were investigated for all markers.
Cytoplasmic IgM.
In combination with CD19/CD34 positivity (pro-B ALL phenotype).